Invesco Nasdaq Biotechnology ETFNASDAQ:IBBQ
- LAST PRICE21.96
- TODAY'S CHANGE (%)-1.07 (-4.65%)
- Bid / Lots21.67/ 93
- Ask / Lots22.40/ 89
- Open / Previous Close22.91 / 23.03
- Day Range
- 52 Week Range
- Volume10,651
- Overall Morningstar Rating3 out of 5 Starsout of 268 funds
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IBBQ |
|---|---|---|
| 09:32 ET | 851 | 22.8 |
| 09:39 ET | 270 | 22.5315 |
| 09:46 ET | 100 | 22.48 |
| 10:24 ET | 1152 | 22.22 |
| 10:27 ET | 116 | 22.1709 |
| 10:31 ET | 100 | 22.1426 |
| 11:00 ET | 100 | 22.062 |
| 11:27 ET | 118 | 22.21 |
| 12:28 ET | 450 | 22.15 |
| 01:15 ET | 100 | 22.12 |
| 01:20 ET | 145 | 22.1 |
| 01:22 ET | 500 | 22.1247 |
| 01:38 ET | 500 | 22.12 |
| 01:44 ET | 100 | 22.13 |
| 01:58 ET | 500 | 22.09 |
| 02:05 ET | 210 | 22.07 |
| 02:09 ET | 500 | 22.06 |
| 02:32 ET | 100 | 22 |
| 03:39 ET | 300 | 22.0496 |
| 03:50 ET | 2600 | 21.9755 |
| 04:00 ET | 2600 | 21.96 |
Daily Premium/Discount
| Date | Daily Premium/Discount |
|---|---|
| 08/20/2024 | 0.08% |
| 08/21/2024 Largest Discount | -0.16% |
| 08/22/2024 | 0.12% |
| 08/23/2024 | -0.04% |
| 08/26/2024 | -0.12% |
| 08/27/2024 | -0.08% |
| 08/28/2024 | -0.08% |
| 08/29/2024 | -0.08% |
| 08/30/2024 | 0.08% |
| 09/03/2024 | 0.12% |
| 09/04/2024 | 0.08% |
| 09/05/2024 | -0.13% |
| 09/09/2024 | -0.13% |
| 09/10/2024 | -0.08% |
| 09/11/2024 | 0.12% |
| 09/12/2024 | 0.12% |
| 09/13/2024 | 0.08% |
| 09/16/2024 | 0.08% |
| 09/17/2024 | 0.12% |
| 09/18/2024 | 0.12% |
| 09/19/2024 | 0.08% |
| 09/20/2024 | 0.08% |
| 09/23/2024 | -0.08% |
| 09/24/2024 | -0.13% |
| 09/25/2024 | -0.01% |
| 09/26/2024 | 0.01% |
| 09/27/2024 | 0.04% |
| 09/30/2024 | -0.13% |
| 10/01/2024 | -0.08% |
| 10/02/2024 | -0.13% |
| 10/03/2024 | -0.09% |
| 10/04/2024 | 0.09% |
| 10/07/2024 | 0.13% |
| 10/08/2024 | 0.09% |
| 10/09/2024 | -0.04% |
| 10/10/2024 | 0.00% |
| 10/11/2024 | 0.08% |
| 10/14/2024 | 0.13% |
| 10/15/2024 | -0.04% |
| 10/16/2024 | 0.08% |
| 10/17/2024 | -0.08% |
| 10/18/2024 | -0.08% |
| 10/21/2024 | 0.08% |
| 10/22/2024 | -0.08% |
| 10/23/2024 | 0.09% |
| 10/24/2024 | 0.13% |
| 10/25/2024 | -0.09% |
| 10/28/2024 | 0.00% |
| 10/29/2024 | 0.13% |
| 10/30/2024 Largest Premium | 0.17% |
| 10/31/2024 | -0.09% |
| 11/01/2024 | 0.09% |
| 11/04/2024 | -0.08% |
| 11/05/2024 | -0.08% |
| 11/06/2024 | -0.12% |
| 11/08/2024 | -0.04% |
| 11/11/2024 | -0.08% |
| 11/12/2024 | 0.13% |
| 11/13/2024 | -0.08% |
| 11/14/2024 | 0.13% |
| 11/15/2024 | -0.09% |
| US Stock | 87.8% |
|---|---|
| Non-US Stock | 12.2% |
| Cash | 0.0% |
| Convertible | 0 |
| Non-US Bond | 0 |
| Other | 0 |
| Healthcare | 100.0% |
|---|---|
| Basic Mat. | 0 |
| Communication Services | 0 |
| Consumer Cyclical | 0 |
| Consumer Defensive | 0 |
| Energy | 0 |
| Financial Serv.s | 0 |
| Industrials | 0 |
| Real Estate | 0 |
| Technology | 0 |
| Utilities | 0 |
| United States | 87.9% |
|---|---|
| Europe | 3.4% |
| Canada | 0.4% |
| Asia/Oceania | 0.2% |
| Africa | 0 |
| Latin America | 0 |
| Company Name sortable | Position sortable | Allocation sortable | Allocation sortable1 Month Change | Market Value sortable |
|---|---|---|---|---|
Gilead Sciences Inc | Long | 9.5% | 0.00% | $3.6M |
Vertex Pharmaceuticals Inc | Long | 8.1% | 0.00% | $3.1M |
Amgen Inc | Long | 8.1% | 0.00% | $3.1M |
Regeneron Pharmaceuticals Inc | Long | 6.0% | 0.00% | $2.3M |
AstraZeneca PLC ADR | Long | 4.2% | 0.00% | $1.6M |
Alnylam Pharmaceuticals Inc | Long | 3.5% | 0.00% | $1.3M |
Biogen Inc | Long | 2.6% | 0.00% | $979.4K |
Illumina Inc | Long | 2.3% | 0.00% | $886.2K |
Moderna Inc | Long | 2.1% | 0.00% | $807.6K |
argenx SE ADR | Long | 1.9% | 0.00% | $727.6K |
Reports
- ManagedInvestmentETF11/10/24
Morningstar ETF Report
The Morningstar ETF Report offers in-depth analyst research on exchange-traded funds to help you evaluate these investments and how they fit within a portfolio.
Morningstar Ratings
| Time Horizon | Star Rating |
|---|---|
| Overall Rating | 3 out of 5 Stars |
| 3 Year Rating | 3 out of 5 Stars |
| 5 Year Rating | Not Rated |
| 10 Year Rating | Not Rated |
Past performance is no guarantee of future results. The ratings reflect historical risk-adjusted performance, and the overall rating is derived from a weight average of the fund's 3, 5, and 10 year (Morningstar Rating) metrics.
Style Box is calculated only using the long position holdings of the portfolio.
Best Fit Index | NASDAQ Biotechnology TR USD |
|---|---|
Category | |
Sponsor | Invesco Capital Management LLC |
Inception | June 9, 2021 |
The investment seeks to track the investment results (before fees and expenses) of the Nasdaq Biotechnology Index ®. The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
| Total Net Assets | $38.4M |
|---|---|
| Shares Out. | 1.8M |
| Net Asset Value (NAV) | $21.98 |
| Prem/Discount to NAV | -0.09% |
| P/E Ratio | --- |
| Dividend Yield | 1.08% |
| Dividend per Share | 0.24 USD |
| Ex-Dividend Date | 09/23/2024 |
| Dividend Payment Date | 09/27/2024 |
| Beta | --- |
| Morningstar Investment Style | Health |
| Equity Style | Mid Cap Blend |
| Credit Quality / Duration | --- |
| Actual Management Fee | 0.19% |
|---|---|
| Actual Mgmt. Expense Ratio (MER) | 0.19% |